• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by RayzeBio Inc.

    3/7/24 4:07:39 PM ET
    $RYZB
    Get the next $RYZB alert in real time by email
    15-12G 1 ef20023513_1512g.htm 15-12G
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

    FORM 15



    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
    OF THE SECURITIES EXCHANGE ACT OF 1934.
     
    Commission File Number: 001-41799


     
    RayzeBio, Inc.
    (Exact name of registrant as specified in its charter)
     


    5505 Morehouse Drive, Suite 300
    San Diego, California 92121
     
    (619) 937-2754
    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
     
    Common Stock, par value $0.0001 per share
    (Title of each class of securities covered by this Form)
     
    None
    (Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)



    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:  

    Rule 12g-4(a)(1)
    ☒
    Rule 12g-4(a)(2)
    ☐
    Rule 12h-3(b)(1)(i)
    ☒
    Rule 12h-3(b)(1)(ii)
    ☐
    Rule 15d-6
    ☐
    Rule 15d-22(b)
    ☐
     
    Approximate number of holders of record as of the certification or notice date: One (1) holder.
     


    Pursuant to the requirements of the Securities Exchange Act of 1934, RayzeBio, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

       
    RayzeBio, Inc.
         
       
    By:
    /s/ Kimberly M. Jablonski
       
    Name:
    Kimberly M. Jablonski
       
    Title:
    Vice President and Secretary
           
     
    Date: March 7, 2024
     



    Get the next $RYZB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RYZB

    DatePrice TargetRatingAnalyst
    10/11/2023Outperform
    Evercore ISI
    10/10/2023$29.00Buy
    Truist
    10/10/2023$35.00Buy
    Jefferies
    10/10/2023$30.00Overweight
    JP Morgan
    10/6/2023Outperform
    William Blair
    More analyst ratings

    $RYZB
    Leadership Updates

    Live Leadership Updates

    See more
    • RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors

      SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (NASDAQ:RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the appointment of Tim Van Hauwermeiren to its board of directors. As co-founder and CEO of argenx, Tim has built a reputation for his strong execution and innovation, leading argenx from early-stage development into a global immunology company. "RayzeBio has the potential to transform the oncology treatment landscape through targeted radiopharmaceuticals. I see a lot of parallels between RayzeBio and argenx and look forward to leveraging my experience to help RayzeBio unlock the full pote

      11/1/23 6:00:00 AM ET
      $RYZB

    $RYZB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by RayzeBio Inc. (Amendment)

      SC 13G/A - RayzeBio, Inc. (0001825367) (Subject)

      2/28/24 4:28:08 PM ET
      $RYZB

    $RYZB
    SEC Filings

    See more
    • SEC Form 15-12G filed by RayzeBio Inc.

      15-12G - RayzeBio, Inc. (0001825367) (Filer)

      3/7/24 4:07:39 PM ET
      $RYZB
    • SEC Form S-8 POS filed by RayzeBio Inc.

      S-8 POS - RayzeBio, Inc. (0001825367) (Filer)

      2/26/24 9:20:50 AM ET
      $RYZB
    • RayzeBio Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits

      8-K - RayzeBio, Inc. (0001825367) (Filer)

      2/26/24 9:20:10 AM ET
      $RYZB

    $RYZB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Axonis Therapeutics Announces $115 Million Series A Financing

      -- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent

      10/30/24 6:00:00 AM ET
      $AKRO
      $APLS
      $AUPH
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Chemicals
      Consumer Durables
    • venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies

      - venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo

      8/1/24 8:00:00 AM ET
      $AKRO
      $APLS
      $AUPH
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Chemicals
      Consumer Durables
    • Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform

      Adds RYZ101, an IND Engine and Manufacturing Capability, to BMS Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ:RYZB). With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb. "We are excited to complete this transaction, which adds radiopharmaceutical therapeutics (RPTs), one of the fastest-growing new modalities for treating patients with solid tumors," said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb. "By strengthening and further diversifying our oncology pipeline bey

      2/26/24 8:35:00 AM ET
      $BMY
      $RYZB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYZB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Viking Global Investors Lp disposed of 6,642,700 shares (SEC Form 4)

      4 - RayzeBio, Inc. (0001825367) (Issuer)

      2/28/24 4:28:49 PM ET
      $RYZB
    • Viking Global Investors Lp disposed of 6,642,700 shares (SEC Form 4)

      4 - RayzeBio, Inc. (0001825367) (Issuer)

      2/28/24 4:30:12 PM ET
      $RYZB
    • SEC Form 4 filed by Oliger Christy J.

      4 - RayzeBio, Inc. (0001825367) (Issuer)

      2/27/24 5:14:07 PM ET
      $RYZB

    $RYZB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on RayzeBio

      Evercore ISI initiated coverage of RayzeBio with a rating of Outperform

      10/11/23 7:52:46 AM ET
      $RYZB
    • Truist initiated coverage on RayzeBio with a new price target

      Truist initiated coverage of RayzeBio with a rating of Buy and set a new price target of $29.00

      10/10/23 7:32:40 AM ET
      $RYZB
    • Jefferies initiated coverage on RayzeBio with a new price target

      Jefferies initiated coverage of RayzeBio with a rating of Buy and set a new price target of $35.00

      10/10/23 7:31:44 AM ET
      $RYZB

    $RYZB
    Financials

    Live finance-specific insights

    See more
    • Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform

      Adds RYZ101, an IND Engine and Manufacturing Capability, to BMS Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ:RYZB). With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb. "We are excited to complete this transaction, which adds radiopharmaceutical therapeutics (RPTs), one of the fastest-growing new modalities for treating patients with solid tumors," said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb. "By strengthening and further diversifying our oncology pipeline bey

      2/26/24 8:35:00 AM ET
      $BMY
      $RYZB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

      Transaction Brings RayzeBio's Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb's Leading Oncology Franchise Lead Program, RYZ101, in Phase 3 Development for Treatment of Gastroenteropancreatic Neuroendocrine Tumors and Early-stage Development for Treatment of Small Cell Lung Cancer and Potentially Other Tumor Types Gains Robust IND Engine and State of the Art Radiopharmaceutical Manufacturing Capabilities PRINCETON, N.J. and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Bristol Myers Squibb (NYSE:BMY) and RayzeBio, Inc. (NASDAQ:RYZB) today announced a definitive merger agreement under which

      12/26/23 7:13:25 AM ET
      $BMY
      $RYZB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

       Transaction Brings RayzeBio's Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs, to Bristol Myers Squibb's Leading Oncology Franchise Lead Program, RYZ101, in Phase 3 Development for Treatment of Gastroenteropancreatic Neuroendocrine Tumors and Early-stage Development for Treatment of Small Cell Lung Cancer and Potentially Other Tumor Types Gains Robust IND Engine and State-of-the-Art Radiopharmaceutical Manufacturing Capabilities Bristol Myers Squibb (NYSE:BMY) and RayzeBio, Inc. (NASDAQ:RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per shar

      12/26/23 6:59:00 AM ET
      $BMY
      $RYZB
      Biotechnology: Pharmaceutical Preparations
      Health Care